Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Korea Pharma Co., Ltd. (032300:KRX), powered by AI.
Korea Pharma Co., Ltd. is currently trading at ₩8,930. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Korea Pharma Co., Ltd. on Alpha Lenz.
Korea Pharma Co., Ltd.'s P/E ratio is -37.0.
“Korea Pharma Co., Ltd. trades at a P/E of -37.0 (undervalued) with modest ROE of -3.8%.”
Ask for details →Korea Pharma Co., Ltd. is a prominent entity in the pharmaceutical industry, primarily focused on the research, development, and production of high-quality pharmaceutical products. The company specializes in a wide array of medications, including prescription drugs and over-the-counter treatments, catering to various health needs and conditions. Korea Pharma Co., Ltd. is known for its commitment to innovation in pharmaceutical technologies, contributing significantly to advancements in medicine. It serves diverse markets encompassing hospitals, pharmacies, and direct consumer sales channels. The company plays a crucial role in the healthcare sector, enhancing accessibility to essential medicines and meeting the growing demand for healthcare solutions in South Korea and beyond. As an integral player in the pharmaceutical landscape, Korea Pharma actively participates in improving healthcare standards through rigorous quality control and compliance with international health regulations. Its efforts in pharmaceutical research and production uphold the company’s reputation as a trustworthy provider of medicinal products and solutions.
“Korea Pharma Co., Ltd. trades at a P/E of -37.0 (undervalued) with modest ROE of -3.8%.”
Ask for details →Korea Pharma Co., Ltd. (ticker: 032300) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $97.6B.
The current price is ₩8,930 with a P/E ratio of -36.97x and P/B of 1.42x.
ROE is -3.77% and operating margin is -1.01%. Annual revenue is $87.6B.